CareLit Fachartikel

B lymphocyte stimulator (BLyS) is a novel adipokine in humans in vivo being related to obesity but not to insulin resistance

N Müller, S Hillebrand, DM Schulte, K Türk, K Neumann, M Stelmach-Mardas, J Hampe, C Schafmayer, M Brosch, W von Schönfels, M Ahrens, C Gutschow, R Zeuner, JO Schröder, M Blüher, S Schreiber, M Laudes · Diabetologie und Stoffwechsel · 2013 · Heft 04

Dokument
1111523
CareLit-ID
Jahr
2013
Publikation
PDF
nein
Metadaten
DOI
ja
zitierfähig

Bibliografische Angaben

Zeitschrift
Diabetologie und Stoffwechsel
Autor:innen
N Müller, S Hillebrand, DM Schulte, K Türk, K Neumann, M Stelmach-Mardas, J Hampe, C Schafmayer, M Brosch, W von Schönfels, M Ahrens, C Gutschow, R Zeuner, JO Schröder, M Blüher, S Schreiber, M Laudes
Ausgabe
Heft 04 / 2013
Seiten
–
Erschienen: 2013-04-19 00:00:00
ISSN
1861-9002
DOI
10.1055/s-0033-1341837

Zusammenfassung

Background and Objective: B lymphocyte stimulator (BLyS) was considered as a novel adipokine in mice inducing low-grade inflammation and insulin resistance in obesity. Therefore, our aim was to examine (1) whether BLyS expression in human adipocytes in vivo differs between lean and obese ± insulin resistant subjects, (2) whether BLyS serum concentrations are dysregulated in obesity ± insulin resistance, (3) whether BLyS responds to different weight loss therapies and (4) whether inhibition of BLyS in humans in vivo by a neutralizing antibody (belimumab) alters insulin sensitivity. Methodology: BLyS expression in…

Schlagworte

Obesity Adipokine Bariatric Surgery Adipocytes Affect Diet Diabetologie und Stoffwechsel